Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain
MWN-AI** Summary
Aclarion, Inc., a healthcare technology company focused on chronic low back pain, recently announced the issuance of U.S. Patent #12,601,803, which covers its innovative, AI-driven platform designed for analyzing magnetic resonance spectroscopy (MRS) data. This patent enhances Aclarion's capabilities by protecting its proprietary AI methodologies that automate biomarker identification and report generation, thus improving workflow efficiency. The company's cloud-based platform, Nociscan, translates complex spectral data into actionable insights to help physicians differentiate between painful and non-painful spinal discs.
Brent Ness, Aclarion’s CEO, emphasized that this patent solidifies the foundation of their MRS-based offering, allowing for significant scalability and margin expansion within a market that sees approximately 266 million individuals affected by chronic low back pain globally. The patent includes provisions for machine learning models that will extract quantitative biomarkers from MRS data, ensuring high-quality, reliable outputs across various imaging systems.
In total, Aclarion's intellectual property portfolio now encompasses 64 issued and pending patents globally, strengthening its competitive landscape in the growing chronic low back pain sector. With evidence demonstrating that Nociscan can achieve a surgical success rate of up to 97% when paired with other diagnostic methods, the technology is positioned to revolutionize pain assessment practices.
Aclarion's strategic focus combines advanced signal processing and machine learning, targeting the significant clinical gap in chronic low back pain diagnosis. As this innovative platform gains traction, it reflects Aclarion's commitment to enhancing treatment precision and efficacy, providing healthcare providers with invaluable insights to optimize patient management.
MWN-AI** Analysis
Aclarion, Inc. has recently secured a significant competitive advantage by obtaining U.S. Patent #12,601,803, which bolsters its AI-driven assessment of chronic low back pain through its innovative Nociscan platform. This patent not only expands the firm's intellectual property portfolio to 64 patents worldwide but also fortifies its long-term market position in the rapidly growing healthcare technology sector.
Investors should take note of the implications of this patent. With the chronic low back pain market—affecting approximately 266 million people globally—remaining largely underserved, Aclarion is strategically positioned to capitalize on a significant opportunity. The ability to leverage AI for enhanced report generation and automated data quality controls should both accelerate the product's scalability and improve gross margins, a critical metric for profitability in this sector.
The management's emphasis on using proprietary machine learning algorithms to transform complex MRS data into meaningful clinical insights highlights a clear path to streamlining healthcare practices, which may potentially yield a high surgical success rate when combined with conventional diagnostic tools. Aclarion's technology could redefine treatment methodologies, representing a promising advancement that could lead to broader clinical adoption.
For investors, Aclarion appears to be an attractive opportunity, particularly as interest in data-driven healthcare solutions continues to surge. However, one must remain cognizant of inherent risks, including potential regulatory hurdles and market competition. Monitoring Aclarion's progress in expanding Nociscan's adoption and its execution strategy will be essential for assessing future performance.
In conclusion, Aclarion's innovative approach backed by a robust patent portfolio positions it favorably in the market. Stakeholders should watch developments closely, as successful scaling could unlock significant value for investors in the coming years.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Patent covers use of AI in workflows of future products to accelerate company’s ability to scale and enhance already strong gross margins
- Expands intellectual property portfolio to 64 issued and pending patents worldwide, strengthening long-term competitive moat
BROOMFIELD, Colo., April 16, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the issuance of U.S. Patent #12,601,803, titled “System for Machine Learning-Based Model Training and Prediction for Evaluation of Pain,” covering its machine learning–based platform for analyzing magnetic resonance spectroscopy (MRS) data.
Aclarion’s cloud-based platform, Nociscan, converts complex MRS spectral data into clinically actionable insights to help physicians distinguish between painful and non-painful discs in the spine. The newly issued patent strengthens Aclarion’s ability to scale by protecting its use of AI in future versions of the platform to further automate biomarker identification, accelerate report generation and reduce manual quality reviews.
“This patent strengthens the foundation of our platform by protecting how we leverage AI to transform complex spectroscopy data into meaningful, actionable information that physicians can integrate into everyday practice,” said Brent Ness, Chief Executive Officer of Aclarion. “By combining proprietary signal processing with machine learning, we are building a scalable and defensible approach to evaluating pain that has the potential to redefine how spine conditions are assessed while enabling highly efficient scaling and strong gross margin expansion.”
The patent covers machine learning models that extract quantitative biomarkers from MRS spectral data to generate standardized classifications associated with pain-related conditions. Importantly, the patent also covers AI-based automated data quality controls that detect and exclude low-quality acquisition signals, such as excessive lipids, low signal-to-noise ratio, or spectral artifacts. This capability will enable consistent, reproducible outputs across imaging systems and sites and represents a key step toward broader clinical adoption.
The patent further expands Aclarion’s intellectual property portfolio, with 64 issued and pending patents worldwide, and underscores its strategy to build a differentiated, software-driven platform in the large and underserved chronic low back pain market. Chronic low back pain is a significant global healthcare challenge, affecting approximately 266 million people worldwide. When used alongside other diagnostic tools, clinical data has demonstrated up to a 97% surgical success rate when all Nociscan-positive discs are treated.
To read the patent, click here.
For more News from Aclarion, please visit: Latest News
To find a Nociscan center, view our site map here.
For more information on Nociscan, please email: info@aclarion.com
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding Aclarion Highlights Growing Adoption of Nociscan at The London Clinic, and the potential benefits of our Nociscan technology. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com
Media Contacts:
Jennie Kim
SPRIG Consulting
jennie@sprigconsulting.com
FAQ**
How does Aclarion Inc. ACON plan to leverage its newly issued patent to enhance the accuracy and efficiency of its Nociscan platform while maintaining strong gross margins in a competitive healthcare technology market?
What specific strategies will Aclarion Inc. ACON implement to scale its AI-driven workflows in Nociscan and ensure widespread clinical adoption of its diagnostic technology for chronic low back pain?
In what ways does Aclarion Inc. ACON anticipate that its expanding intellectual property portfolio will provide a sustainable competitive advantage in the rapidly evolving landscape of healthcare technology?
How does the integration of automated data quality controls covered by Aclarion Inc. ACON's patent improve the reliability of MRS data analysis for spine condition evaluations compared to existing diagnostic methods?
**MWN-AI FAQ is based on asking OpenAI questions about Aclarion Inc. (NASDAQ: ACON).
NASDAQ: ACON
ACON Trading
-4.06% G/L:
$3.425 Last:
49,457 Volume:
$3.49 Open:
